Gilbert S. Omenn, MD, PhD, is Harold T. Shapiro Distinguished University Professor of Computational Medicine Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan. He was a Howard Hughes Medical Institute Investigator, longtime NCI-funded PI, physician genetic counselor at the University of Washington and CEO of the University of Michigan Health System. His research focus is proteogenomics of cancers. He chaired the global Human Proteome Project. He was president of AAAS; chaired the Presidential/ Congressional Commission on Risk Assessment and Risk Management and the Institute of Medicine 2012 report on Evolution of Translational Omics, and served on the boards of Amgen, Rohm Haas, Galectin, and Oncopia. Currently he is on the boards of Hastings Center for Bioethics, Center for Public Integrity, and Weizmann Institute..He has participated in the Personalized Medicine World Conferences for more than a decade.
Data Sciences for Proteogenomics of Cancers
NCI CPTAC-led multi-omics analyses of the molecular features of cancers identify drivers of proliferation and metastasis, subtypes of cancers and intra-tumoral heterogeneity, and targets for precision chemotherapy and immunotherapy, illustrated with clear cell renal adenocarcinomas.